173315-56-5

Basic information

• Product Name: 2-chloro-4-fluoro-3-methyl-5-nitrobenzoic acid
• Synonyms: 2-chloro-4-fluoro-3-methyl-5-nitrobenzoic acid
• CAS NO: 173315-56-5
• Molecular Weight: 233.583
• Mol File: 173315-56-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-chloro-4-fluoro-3-methyl-5-nitrobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-4-fluoro-3-methyl-5-nitrobenzoic acid(173315-56-5)
• EPA Substance Registry System: 2-chloro-4-fluoro-3-methyl-5-nitrobenzoic acid(173315-56-5)

Safety Data

• Hazardous Substances Data: 173315-56-5(Hazardous Substances Data)

Upstream product

• 443-83-4 2-chloro-6-fluorotoluene 
• 75-36-5 acetyl chloride 
• 173315-54-3 2-chloro-4-fluoro-3-methylbenzoic acid 

Downstream Products

• 173315-65-6 2-chloro-4-fluoro-3-methyl-5-nitrobenzoyl chloride 
• 1026687-25-1 1-(4-Methoxy-phenyl)-8-methyl-7-(4-methyl-piperazin-1-yl)-6-nitro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 1027145-27-2 1-(4-Fluoro-phenyl)-8-methyl-7-(4-methyl-piperazin-1-yl)-6-nitro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 1026536-30-0 6-Amino-1-(4-methoxy-phenyl)-8-methyl-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 1026741-19-4 6-Amino-1-(4-fluoro-phenyl)-8-methyl-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 148927-23-5 MF5137 
• 173315-67-8 7-Fluoro-1-(4-methoxy-phenyl)-8-methyl-6-nitro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 173315-66-7 7-Fluoro-1-(4-fluoro-phenyl)-8-methyl-6-nitro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 173315-57-6 ethyl 2-(2-chloro-4-fluoro-3-methyl-5-nitrobenzoyl)-3-(dimethylamino)acrylate 
• 1380836-63-4 2-chloro-3-methyl-4-methylamino-5-nitro-benzoic acid 

Relevant articles and documents

Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity

MLL1-WDR5 interaction is essential for the formation of MLL core complex and its H3K4 methyltransferase activity. Disrupting MLL1-WDR5 interaction has been proposed as a potential therapeutic approach in the treatment of leukemia. A “toolkit” of well-characterized chemical probe will allow exploring animal studies. Based on a specific MLL1-WDR5 PPI inhibitor (DDO-2117), which was previously reported by our group, we conducted a bioisosterism approach by click chemistry to discover novel phenyltriazole scaffold MLL1-WDR5 interaction blockers. Here, our efforts resulted in the best inhibitor 24 (DDO-2093) with high binding affinity (Kd = 11.6 nM) and with improved drug-like properties. Both in vitro and in vivo assays revealed 24 could efficiently block the MLL1-WDR5 interaction. Furthermore, 24 significantly suppressed tumor growth in the MV4-11 xenograft mouse model and showed a favorable safety profile. We propose 24 as a chemical probe that is suitable for in vivo pharmacodynamic and biological studies of MLL1-WDR5 interaction.

Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5

MLL1 complex catalyzes the methylation of H3K4, and plays important roles in the development of acute leukemia harboring MLL fusion proteins. Targeting MLL1-WDR5 protein-protein interaction (PPI) to inhibit the activity of histone methyltransferase of MLL1 complex is a novel strategy for treating of acute leukemia. WDR5-47 (IC50 = 0.3 μM) was defined as a potent small molecule to disturb the interaction of MLL1-WDR5. Here, we described structure-based design and synthesis of small molecular inhibitors to block MLL1-WDR5 PPI. Especially, compound 23 (IC50 = 104 nM) was the most potent small molecular, and about 3-times more potent than WDR5-47. We also discussed the SAR of these series of compounds with docking study, which may stimulate more potent compounds.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R1, R2, R3, R4, R6, R7, R9, Ra, Rb have meanings given in the description.